Short answer
MAXCYTE, INC. (MXCT) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $5M (down 15.2% year over year) with net income of −$9M.
Q2 2026 key financials · XBRL
- Revenue
- $5M
- −15.2% YoY · +9.7% QoQ
- Net income
- −$9M
- +28.2% YoY · −86.8% QoQ
- Operating margin
- -207.3%
- Gross margin
- 113.4%
- EPS (diluted)
- −$0.09
- +18.2% YoY · −125.0% QoQ
Source: XBRL data from the MAXCYTE, INC. (MXCT) Q2 2026 10-Q on SEC EDGAR. USD.
MAXCYTE, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No Risk Factors section provided in the submitted filing text
- No new or changed quarterly risks identifiable from the provided excerpt
- $10 million share-repurchase authorization announced May 12, 2026
- 1,313,066 shares repurchased at average $1.13 through June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MAXCYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.